Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02642393
Recruitment Status : Completed
First Posted : December 30, 2015
Results First Posted : July 28, 2020
Last Update Posted : July 28, 2020
Sponsor:
Collaborators:
The Parkinson Study Group
Michael J. Fox Foundation for Parkinson's Research
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Michael Alan Schwarzschild, Massachusetts General Hospital

Tracking Information
First Submitted Date  ICMJE December 19, 2015
First Posted Date  ICMJE December 30, 2015
Results First Submitted Date  ICMJE May 26, 2020
Results First Posted Date  ICMJE July 28, 2020
Last Update Posted Date July 28, 2020
Actual Study Start Date  ICMJE June 2016
Actual Primary Completion Date June 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 8, 2020)
Rate of Clinical Decline [ Time Frame: two years ]
The primary outcome of the trial is rate of change in the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) I-III total score over 24 months estimated from a shared-baseline, random-slopes mixed model, censoring follow-up of subjects after initiation of dopaminergic therapy. Parts I-III of the MDS-UPDRS include ratings of non-motor experiences of daily living, motor experiences of daily living, and a motor examination. The MDS-UPDRS is assessed on a 5-point Likert scale ranging from 0 to 4 where higher scores imply worse symptoms. Parts I-III contain 59 total questions (13 in Part I, 13 in Part II, and 33 in Part III). Total scores for Parts I-III are calculated as simple sums of component items with mean imputation by Part if no more than 1, 2, or 7 items are missing for Parts I through III, respectively. Total scores may range from 0 to 236, with 0 meaning no symptoms and 236 meaning worse symptoms.
Original Primary Outcome Measures  ICMJE
 (submitted: December 26, 2015)
Rate of Clinical Decline [ Time Frame: two years ]
The primary outcome of the trial is rate of change in MDS-UPDRS I-III total score over 24 months estimated from a shared-baseline, random-slopes mixed model, censoring follow-up of subjects after initiation of dopaminergic therapy.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 8, 2020)
  • Rate of Developing Adverse Effects [ Time Frame: two years ]
    Safety also will be evaluated by comparing active vs. placebo treatment with respect to overall adverse event (AE) and serious AE (SAE) rate.
  • Percentage Developing Adverse Effects [ Time Frame: two years ]
    Safety of oral inosine titrated to elevate trough serum urate to 7.1 - 8.0 mg/dL will be evaluated by comparing active vs. placebo treatment with respect to the percentage of subjects experiencing individual types of AE, as classified by Medical Dictionary for Regulatory Activities (MedDRA) preferred term and system organ class.
  • Percentage of Subjects Tolerant of the Treatment [ Time Frame: three months; two years ]
    Tolerability of a treatment will be defined as a percentage of all subjects in a treatment group who are tolerant of the treatment at 12 weeks (short-term tolerability) and 24 months (long-term tolerability). A subject who is tolerant of treatment will be defined as one who remains on-study and on the assigned treatment without one or more dose reductions lasting more than 4 weeks cumulative due to AEs. A treatment will be declared tolerable if the percentage who are tolerant is significantly greater than 50% by one-tailed testing at p < 0.05.
  • Percentage of Participants Developing Disability Warranting Dopaminergic Therapy Over Time [ Time Frame: two years ]
    The percentage of participants with disability warranting the initiation of dopaminergic therapy in each treatment group at time from baseline visit (in 180 day increments).
  • Clinical Efficacy: Rate of Change in Parkinson's Disease Questionnaire - 39 Item Version (PDQ-39) Scale [ Time Frame: two years ]
    Rate of change in Parkinson's Disease Questionnaire - 39 item version (PDQ-39) scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The PDQ-39 asks 39 questions organized over eight domains (scales): mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items), and bodily discomfort (3 items). Each item has five possible ordinal responses, from never to always, depending on frequency of the symptom over the preceding month. The eight scales' scores are generated by Likert's method of summated ratings and then transformed to a single figure that ranges from 0 to 100. Higher scores are associated with more symptoms.
  • Clinical Efficacy: Rate of Change in Quality of Life in Neurological Disorders (Neuro-QOL) [ Time Frame: two years ]
    Rate of change in Quality of Life in Neurological Disorders (Neuro-QOL) scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. Neuro-QOL is a set of patient-reported outcome (PRO) measures that assess health-related quality of life (HRQoL) of people with neurological disorders. It comprises 17 domains of HRQL covering physical, psychological and social health. Domains tested include anxiety, cognitive function, communication, depression, emotional and behavioral dyscontrol, fatigue, lower extremity function- mobility, positive affect and well- being, stigma, upper extremity function- fine motor and ADL, sleep disturbance, satisfaction with social roles and activities, and ability to participate in social roles and activities. Higher raw scores are associated with more of the concept being measured. All scales range from 8 to 40 except for Positive Affect and Well-Being which ranges from 9 to 45.
  • Clinical Efficacy: Rate of Change in Quality of Life in Neurological Disorders (Neuro-QOL) Depression Module [ Time Frame: two years ]
    Rate of change in Quality of Life in Neurological Disorders (Neuro-QOL) depression module scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. Neuro-QOL is a set of patient-reported outcome (PRO) measures that assess health-related quality of life (HRQoL) of people with neurological disorders. Higher raw scores are associated with more of the concept being measured. The depression module score ranges from 8 to 40.
  • Clinical Efficacy: Rate of Change in Schwab and England Scale [ Time Frame: two years ]
    Rate of change in percentage points on the Schwab and England scale for functional disability (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The Schwab and England scale is a Site Investigator and subject assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living. Printed scores with associated descriptors range from 0% to 100% in increments of 5%, with higher percentages associated with more independence. A score of 0% implies "vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden". A score of 100% implies "subject has full ability and is completely independent; essentially normal".
  • Clinical Efficacy: Rate of Change in Montreal Cognitive Assessment (MoCA) [ Time Frame: two years ]
    Rate of change in points on the Montreal Cognitive Assessment (MoCA) scale (for cognition; over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group. The MoCA assesses attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Points are awarded for the correct completion of MoCA tasks. Scores for each task are summed for a total score (range 0-30). Higher scores indicate greater cognitive capacity.
  • Symptomatic Effects [ Time Frame: three months (after both initiation and discontinuation of study drug) ]
    Symptomatic effects will be estimated by changes in motor and other features (e.g., as assessed by short-term change in Movement Disorders Society Unified PD Rating Scale [MDS-UPDRS] I-III total score) during the first 3 months of wash-in at the start of period 1 and during the 3-month wash-out of period 2. The MDS-UPDRS includes ratings of non-motor experiences of daily living, motor experiences of daily living, and a motor examination. The MDS-UPDRS is assessed on a 5-point Likert scale ranging from 0 to 4 where higher scores imply worse features. Parts I-III contain 59 total questions (13 in Part I, 13 in Part II, and 33 in Part III). Total scores are calculated as simple sums of component items with mean imputation by Part if no more than 1, 2, or 7 items are missing for Parts I through III, respectively. Total scores may range from 0 to 236, with 0 meaning no symptoms and 236 meaning worse symptoms.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 26, 2015)
  • Rate of Developing Adverse Effects [ Time Frame: two years ]
    Safety also will be evaluated by comparing active vs. placebo treatment with respect to overall adverse event (AE) and serious AE (SAE) rate.
  • Proportion developing adverse effects [ Time Frame: two years ]
    Safety of oral inosine titrated to elevate trough serum urate to 7.1 - 8.0 mg/dL will be evaluated by comparing active vs. placebo treatment with respect to proportions of subjects experiencing individual types of AE, as classified by Medical Dictionary for Regulatory Activities (MedDRA) preferred term and system organ class.
  • Proportion of subjects tolerant of the treatment [ Time Frame: three months; two years ]
    Tolerability of a treatment will be defined as a proportion of all subjects in a treatment group who are tolerant of the treatment at 12 weeks (short-term tolerability) and 24 months (long-term tolerability). A subject who is tolerant of treatment will be defined as one who remains on-study and on the assigned treatment without one or more dose reductions lasting more than 4 weeks cumulative due to AEs. A treatment will be declared tolerable if the proportion who are tolerant is significantly greater than 50% by one-tailed testing at p < 0.05.
  • Time to disability warranting dopaminergic therapy [ Time Frame: two years ]
    Secondary efficacy outcomes will include time from baseline visit to disability warranting the initiation of dopaminergic therapy in each treatment group.
  • Clinical efficacy: Rate of change in PDQ-39 [ Time Frame: two years ]
    Rate of change in PDQ-39 scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group.
  • Clinical efficacy: Rate of change in Neuro-QOL [ Time Frame: two years ]
    Rate of change in Neuro-QOL scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group.
  • Clinical efficacy: Rate of change in Neuro-QOL depression module [ Time Frame: two years ]
    Rate of change in Neuro-QOL depression module scale points (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group.
  • Clinical Efficacy: Rate of Change in Schwab and England Scale [ Time Frame: two years ]
    Rate of change in percentage points on the Schwab and England scale for functional disability (over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group.
  • Clinical Efficacy: Rate of Change in Montreal Cognitive Assessment (MoCA) [ Time Frame: two years ]
    Rate of change in points on the MoCA scale (for cognition; over the time between baseline visit and final visit on study drug) will be assessed for subjects in each treatment group.
  • Clinical efficacy: Proportion of subjects having developed disability warranting dopaminergic therapy [ Time Frame: up to 27 months ]
    Determinations of disability warranting initiation of dopaminergic therapy will be made every three months during period 1 (24 months on study drug) and monthly during period 2 (following study drug discontinuation, between months 24 and 27) for subjects who have not previously reached this level of disability. Analysis of measures that are equally evaluable at the end of both periods (such as proportion of subjects having developed disability warranting dopaminergic therapy), will be conducted as a three-part test: a) of significantly slower worsening during period 1, b) of non-inferior rates of worsening during period 2, and c) of a significant net benefit at the end of period 2. It could provide evidence of disease modification if all three evaluations were favorable.
  • Symptomatic Effects [ Time Frame: three months (after both initiation and discontinuation of study drug) ]
    Symptomatic effects will be estimated by changes in motor and other features (e.g., as assess by short-term change in total MDS-UPDRS score) during the first 3 months of wash-in at the start of period 1 and during the 3-month wash-out of period 2.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Urate Elevation in Parkinson's Disease, Phase 3
Official Title  ICMJE A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease
Brief Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD.

Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

Detailed Description

Capsules containing 500 mg of inosine (active drug) or ~500 mg of lactose (placebo) will be taken orally up to two capsules three times per day (i.e., up to 3 g/day) for 24 months. In the inosine-treated group the number of capsules taken per day will be titrated to serum urate levels - measured at trough at study visits no more than three months apart - in order to achieve concentrations of 7.1-8.0 mg/dL. Initial dosing will be tailored to individualized factors including gender and pretreatment serum urate, and then advanced gradually toward the projected target dose. Adjustments in dosing of placebo capsules in the control arm will be algorithm-based to match dosing of inosine capsules in the active drug arm.

Following study drug discontinuation all subjects will be followed during a 3-month wash-out period by telephone calls and a final study visit. All study visits after screening will include measurement of the primary outcome variable (MDS-UPDRS) and most will include secondary outcome variables: adverse events, dose adjustments, disability warranting initiation of dopaminergic therapy, Quality of Life in Neurological Disorders (Neuro-QOL), 39-item Parkinson's Disease Questionnaire (PDQ-39), Schwab & England Activities of Daily Living (S&E ADL) scale, Montreal Cognitive Assessment (MoCA), and orthostatic vital signs.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Condition  ICMJE Parkinson's Disease
Intervention  ICMJE
  • Drug: Inosine
    capsules containing 500 mg of inosine
    Other Name: hypoxanthine 9-β-D-ribofuranoside
  • Drug: Placebo
    capsules containing ~500 mg of lactose and appearing indistinguishable from inosine capsules
    Other Name: inactive agent
Study Arms  ICMJE
  • Experimental: Inosine
    Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
    Intervention: Drug: Inosine
  • Placebo Comparator: Placebo
    Placebo will be dosed to match the capsule titrations of the inosine group.
    Intervention: Drug: Placebo
Publications * Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 8, 2020)
298
Original Estimated Enrollment  ICMJE
 (submitted: December 26, 2015)
270
Actual Study Completion Date  ICMJE June 2019
Actual Primary Completion Date June 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

INCLUSION CRITERIA:

Study subjects meeting all of the following criteria will be allowed to enroll in the study:

  1. Willingness and ability to give written informed consent and to comply with trial procedures.
  2. Fulfillment of diagnostic criteria for idiopathic PD with at least two of the cardinal signs of PD (resting tremor, bradykinesia, rigidity) present at 2nd screening and baseline evaluations, as assessed by the Site Investigator.
  3. Absence of current or imminent (within 90 days of enrollment) PD disability requiring dopaminergic therapy, as assessed by the Site Investigator.
  4. Modified Hoehn and Yahr Scale Stage 1 to 2.5 inclusive.
  5. Age 30 or older at the time of PD diagnosis.
  6. Diagnosis of PD made within 3 years prior to 1st Screening Visit.
  7. Non-fasting serum urate ≤ 5.7 mg/dL at 1st Screening Visit (SC1).
  8. If the subject is female, then:

    1. Being surgically sterile (hysterectomy or tubal ligation), or
    2. Being postmenopausal (last menstruation was two years or more prior to 2nd Screening Visit), or
    3. For those of childbearing potential

      • Using a reliable form of contraception for 60 days or more prior to Baseline Visit and agreeing to continue such use for 30 days post last dose of study drug. Reliable forms of contraception include: abstinence; implanted, injected or oral contraceptives (birth control pills), intrauterine device in place for at least 3 months prior to Baseline Visit, vaginal ring with spermicide, barrier with spermicide such as male or female condom, diaphragm or cervical cap, transdermal patch; male partner with vasectomy.
      • And having a negative pregnancy test at the 2nd Screening Visit. [Note that a urine pregnancy test will be performed at screening on all women who are not at least two years postmenopausal or surgically sterile.]

EXCLUSION CRITERIA:

Study subjects meeting any of the following criteria during screening evaluations will be excluded from entry into the study:

  1. Atypical parkinsonism, including that due to drugs, metabolic disorders, encephalitis, cerebrovascular disease, normal pressure hydrocephalus, or other neurodegenerative disease.
  2. Dopamine transporter (DAT) brain scan without evidence of dopamine deficit.
  3. History of gout.
  4. History of uric acid or urate urolithiasis, or recurrent urolithiasis all of unknown type.
  5. A screening test positive for uric acid crystalluria, urine pH ≤ 5.0, or an estimated glomerular filtration rate < 60 ml/min/1.73 m2.
  6. History of myocardial infarction or stroke.
  7. Symptomatic congestive heart failure with a documented ejection fraction below 45%.
  8. History of severe chronic obstructive pulmonary disease.
  9. Mini Mental State Exam score < 25; i.e., a score of 0 to 24.
  10. Use of any anti-parkinsonian medication (including levodopa, dopamine agonists, amantadine, entacapone and the anticholinergic agents trihexyphenidyl and benztropine) other than monoamine oxidase-B inhibitors within 60 days of Baseline, or in excess of 90 days.
  11. Change in the dosage of (or initiation of) a monoamine oxidase-B (MAO-B) inhibitor within 90 days prior to Baseline, i.e., entry on a MAO-B inhibitor requires a stable dosage for the 90 days prior to Baseline.
  12. Use of the following within 30 days prior to the Baseline Visit: inosine, allopurinol, febuxostat, probenecid, more than 50 IU of vitamin E daily, or more than 300 mg of vitamin C daily (though a daily standard multivitamin such as Bayer One-A-Day® or Centrum® is permissible), reserpine, methylphenidate, amphetamines, cinnarizine, monoamine oxidase-A inhibitors, tetrabenazine, neuroleptics or other dopamine blocking drugs.
  13. Use of the following within 90 days prior to the DAT neuroimaging screening evaluation: modafinil, armodafinil, metoclopramide, alpha-methyldopa, methylphenidate, reserpine, or amphetamine derivative.
  14. Unstable dosing of a thiazide -- such as hydrochlorothiazide (e.g., Esidrex), chlorothiazide (e.g., Diuril), chlorthalidone (e.g., Hygroton), indapamide (e.g., Lozol), metolazone (e.g., Zaroxolyn), which are permissible as long as the subject is on a stable dose from 1 week prior to the 1st Screening Visit through the Baseline Visit.
  15. Known unstable medical or psychiatric condition that may compromise participation in the study. (Note that difficulty swallowing large capsules might preclude participation due to the size of the study drug capsules.)
  16. Clinically serious abnormality in the screening visit laboratory studies or ECG, as determined by the Site Investigator.
  17. Participation in another investigational treatment study within 30 days prior to the Baseline Visit.
  18. Known hypersensitivity or intolerability to inosine.
  19. Known hypersensitivity to DaTscan (either the active substance of ioflupane I-123 or to any of the excipients).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02642393
Other Study ID Numbers  ICMJE INO-PD-P3-2014
1U01NS090259-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: De-identified data; per policies of NIH/NINDS and the PSG (Parkinson Study Group)
Responsible Party Michael Alan Schwarzschild, Massachusetts General Hospital
Study Sponsor  ICMJE Michael Alan Schwarzschild
Collaborators  ICMJE
  • The Parkinson Study Group
  • Michael J. Fox Foundation for Parkinson's Research
  • University of Rochester
  • National Institute of Neurological Disorders and Stroke (NINDS)
Investigators  ICMJE
Study Chair: Michael A Schwarzschild, MD, PhD Massachusetts General Hospital (PI of Clinical Coordinating Center), PSG (Chair, SURE-PD3 Steering Committee)
Study Director: Alberto Ascherio, MD, DrPH Harvard School of Public Health, PSG (Co-Chair, SURE-PD3 Steering Committee)
Study Director: David Oakes, PhD University of Rochester (PI of Data Coordinating Center), PSG (Study Statistician/Member, SURE-PD3 Steering Committee)
Study Director: Eric A Macklin, PhD Massachusetts General Hospital, PSG (Study Statistician/Member, SURE-PD3 Steering Committee)
PRS Account Massachusetts General Hospital
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP